01—Abstract
Summary
Summary of the 8-K filed April 26, 2024. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. ("West") filed an 8-K on April 26, 2024 reporting two items: a management role change and the results of its 2024 Annual Meeting of Shareholders.
Effective May 1, 2024, Bernard Birkett's title becomes solely Chief Financial Officer ("CFO"). Since May 2022 he had served as both Principal Financial and Principal Operating Officer. He will keep financial oversight of both Business Segments and operational oversight of the strategic sourcing function, and will be involved in key operational issues with the executive team.
The company will no longer have a single principal operating officer, and operational leadership and decision-making will move to each Business Segment to improve efficiency. At the Annual Meeting, held virtually on April 23, 2024, shareholders representing 67,175,691 shares, or 91.76%a of the 73,205,367 common shares outstanding at the February 28, 2024 record date, were present or represented by proxy. All 11 directors were elected to serve until the 2025 Annual Meeting, though several received substantial against votes, including Deborah L.
V. Keller (8,407,056 against) and Thomas W. Hofmann (4,674,914 against).
Shareholders also approved the advisory named executive officer compensation, approved amendments to eliminate the supermajority transaction and amendment requirements, and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2024. Shareholder Proposal 6 was not presented after the SEC issued a No-Action Letter in West's favor, because it duplicated management Proposals 3 and 4.
02—Key points
Key Highlights
- Bernard Birkett's title changes to solely Chief Financial Officer effective May 1, 2024, ending his combined Principal Financial and Principal Operating Officer role held since May 2022.
- West will no longer have a single principal operating officer; operational leadership and decision-making shift to each of its Business Segments.
- Birkett retains financial oversight of both Business Segments and operational oversight of the strategic sourcing function.
- The 2024 Annual Meeting was held virtually on April 23, 2024, with shareholders representing 91.76% of common shares outstanding present or represented by proxy.
- All 11 director nominees were elected to serve until the 2025 Annual Meeting; Deborah L. V. Keller received the most against votes (8,407,056).
- Shareholders approved eliminating the supermajority transaction and amendment requirements in the articles of incorporation.
- Shareholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal 2024 and approved the advisory named executive officer compensation.
03—Questions
Frequently Asked Questions
Why is Bernard Birkett's role changing?
The filing says his combined role since May 2022 greatly enhanced the operations capabilities of both the Proprietary Products and Contract Manufacturing Business Segments. Operational leadership and decision-making are now being transferred to each Business Segment to further improve efficiency.
What are Bernard Birkett's responsibilities after May 1, 2024?
As Chief Financial Officer, he will retain financial oversight for both Business Segments and operational oversight of the strategic sourcing function, and will be involved in key operational issues together with other members of the executive team.
Were all director nominees elected at the 2024 Annual Meeting?
Yes. Each of the 11 named directors was elected to serve on the Board until the 2025 Annual Meeting. Several received notable against votes, including Deborah L. V. Keller with 8,407,056 against and Thomas W. Hofmann with 4,674,914 against.
Why was Shareholder Proposal 6 not presented at the meeting?
After the proxy was published, the SEC issued a No-Action Letter in West's favor regarding the proposal. It was not presented because it was duplicative of management Proposals 3 and 4.
What did shareholders approve regarding governance?
Shareholders approved amending and restating the articles of incorporation to eliminate the supermajority transaction requirement (64,521,017 for) and the supermajority amendment requirement (64,516,512 for).
04—Continue